- A Short Synthesis of Natural (-)-Oblongolide via an Intramolecular or a Transannular Diels-Alder Reaction
-
The absolute configuration on naturally occurring oblongolide is confirmed as (3aS,5aR,7S,9aS,9bS)-3a,5a,6,7,8,9,9a,9b-octahydro-7,9b-dimethylnaphthofuran-1(3H)-one (1) on the basis of a six-stage or an eight-stage synthesis from (-)-citronellol involving a steric-controlled, regioselective reduction and an intramolecular Diels-Alder (IMDA) reaction or a transannular Diels-Alder (TDA) reaction as the key steps. (-)-Citronellol (5) was converted into methyl (2E,4E,10E)-(S)-(+)-11-(tert-butoxycarbonyl)-7-methylundeca-2,4,10-trienoate (7) by sequential Lemiuex-Johnson oxidation, Wittig olefination, pyridinium dichromate oxidation, and Wadsworth-Emmons-Horner alkenation.A regioselective reduction of the methoxycarbonyl group in 7 afforded tert-butyl (2E,8E,10E)-(S)-(+)-2,6-dimethyl-12-hydroxydodeca-2,8,10-trienoate (8) from which oblongolide (1) was obtained via an IMDA reaction.The macrocyclic (2E,8E,10E)-(S)-(+)-2,6-dimethyldodeca-2,8,10-trieno-1,12-lactone derived from 8 underwent a highly stereoselective TDA reaction to give 1 at a lower reaction temperature, in a shorter reaction time and in a better yield than the analogous IMDA reaction.
- Shing, Tony K. M.,Yang, Jun
-
-
Read Online
- Selective Construction of C?C and C=C Bonds by Manganese Catalyzed Coupling of Alcohols with Phosphorus Ylides
-
Herein, we report the manganese catalyzed coupling of alcohols with phosphorus ylides. The selectivity in the coupling of primary alcohols with phosphorus ylides to form carbon-carbon single (C?C) and carbon-carbon double (C=C) bonds can be controlled by the ligands. In the conversion of more challenging secondary alcohols with phosphorus ylides the selectivity towards the formation of C?C vs. C=C bonds can be controlled by the reaction conditions, namely the amount of base. The scope and limitations of the coupling reactions were thoroughly evaluated by the conversion of 21 alcohols and 15 ylides. Notably, compared to existing methods, which are based on precious metal complexes as catalysts, the present catalytic system is based on earth abundant manganese catalysts. The reaction can also be performed in a sequential one-pot reaction generating the phosphorus ylide in situ followed manganese catalyzed C?C and C=C bond formation. Mechanistic studies suggest that the C?C bond was generated via a borrowing hydrogen pathway and the C=C bond formation followed an acceptorless dehydrogenative coupling pathway. (Figure presented.).
- Liu, Xin,Werner, Thomas
-
p. 1096 - 1104
(2020/12/31)
-
- CONJUGATION LINKERS CONTAINING 2,3-DIAMINOSUCCINYL GROUP
-
Provided is a conjugate of a cytotoxic drug/molecule to a cell-binding molecule with a bis-linker (adual-linker) containing a 2, 3-diaminosuccinyl group. It also relates to preparation of the conjugate of a cytotoxic drug/molecule to a cell-binding molecule with the bis-linker, particularly when the drug having functional groups of amino, hydroxyl, diamino, amino-hydroxyl, dihydroxyl, carboxyl, hydrazine, aldehyde and thiol for conjugation with the bis-linker in a specific manner, as well as the therapeutic use of the conjugates.
- -
-
Page/Page column 232-233
(2020/05/19)
-
- A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS
-
The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.
- -
-
Paragraph 000293; 000294
(2021/03/02)
-
- CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE
-
What provided is the conjugation of cytotoxic to a cell-binding molecule with a bis-linker(dual-linker) as shown in Formula (I). It provides bis-linkage methods of making a conjugate of a cytotoxic drug molecule to a cell-binding agent in a specific manner. It also relates to application of the conjugates for the treatment of a cancer, or an autoimmune disease, or an infectious disease.
- -
-
Paragraph 0866-0871
(2020/01/08)
-
- A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS
-
The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.
- -
-
-
- CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS
-
The present invention relates to linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule.
- -
-
Page/Page column 155; 156
(2018/05/27)
-
- SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF
-
The present invention relates to novel linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Z)- butenedioic), or acetylenedicarboxyl group for conjugation of a cytotoxic agent, and/or one or more different functional molecules per linker to a cell-binding molecule, through bridge linking pairs of thiols on the cell-binding molecule specifically. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.
- -
-
-
- Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products
-
Cyclic peptide natural products contain a variety of conserved, nonproteinogenic structural elements such as d-amino acids and amide N-methylation. In addition, many cyclic peptides incorporate γ-amino acids and other elements derived from polyketide synt
- Bockus, Andrew T.,Lexa, Katrina W.,Pye, Cameron R.,Kalgutkar, Amit S.,Gardner, Jarret W.,Hund, Kathryn C.R.,Hewitt, William M.,Schwochert, Joshua A.,Glassey, Emerson,Price, David A.,Mathiowetz, Alan M.,Liras, Spiros,Jacobson, Matthew P.,Lokey, R. Scott
-
supporting information
p. 4581 - 4589
(2015/06/25)
-
- Gold-catalyzed cyclization of tert-butyl allenoate: General synthesis of 2,4-functionalized butenolides
-
AuCl3 efficiently catalyzes cyclization of tert-butyl allenoates into γ-butenolides. Advantage of directly using allenic ester precursor instead of corresponding acid is demonstrated in the synthesis of a variety of 2,4-disubstituted butenolides. A low catalyst loading and mild reaction condition makes this process an attractive alternative over conventional methods using strong Lewis acids.
- Kang, Ji-Eun,Lee, Eun-Sun,Park, Sang-Il,Shin, Seunghoon
-
p. 7431 - 7433
(2007/10/03)
-
- A convenient synthesis of (E)-4-hydroxy-3-methyl-2-butenyl pyrophosphate and its [4-13C]-labeled form
-
The synthesis of (E)-4-hydroxy-3-methyl-2-butenyl pyrophosphate, an intermediate in the deoxyxylulose pathway of isoprenoid biosynthesis, was accomplished by pyrophosphorylation of (E)-4-chloro-2-methyl-2-buten-1-ol. This route enables convenient access to isotopically labeled products, as demonstrated through the preparation of [4-13C]-(E)-4-hydroxy-3-methyl-2-butenyl pyrophosphate in 28% overall yield from [1-13C]-2-bromopropionic acid.
- Giner, José-Luis
-
p. 5457 - 5459
(2007/10/03)
-
- Carbocyclic compounds useful as leukotriene antagonists
-
This invention comprises novel carbocyclic compounds of formula I (wherein A, Z, R11 and R12 are defined in the specification) derived from acylsulfonamide derivatives of α-carbocyclyltoluic acids wherein said compounds of formula I antagonize the actions of one or more of the arachidonic acid metabolites known as leukotrienes. The invention also provides pharmaceutically acceptable salts of the formula I compounds; pharmaceutical compositions containing the formula I compound, or their salts, for use in the treatment of, for example, allergic or inflammatory diseases, or endotoxic or traumatic shock conditions; and processes for the manufacture of the formula I compounds, as well as intermediates for use in such manufacture.
- -
-
-
- Heter-aliphatic carboxamides
-
This invention provides a series of novel heter-aliphatic carboxamides of formula I in which the group >Z--Y--XC=CH--NN--CH=CC=N--NN--N=C and the other radicals have the meanings defined in the following specification. The compounds of formula I are leukotriene antagonists. The invention also provides pharmaceutically acceptable salts of the formula I compounds; pharmaceutical compositions containing the formula I compound, or their salts, for use in the treatment of, for example, allergic or inflammatory diseases, or endotoxic or traumatic shock conditions; and processes for the manufacture of the formula I compounds, as well as intermediates for use in such manufacture.
- -
-
-
- Aliphatic carboxamides
-
This invention provides a series of novel heterocyclic aliphatic carboxamides of formula I in which the group >Z--Y--XC=CH--NN--CH=CC=N--NN--N=C and the other radicals have the meanings defined in the following specification. The compounds of formula I are leukotriene antagonists. The invention also provides pharmaceutically acceptable salts of the formula I compounds; pharmaceutical compositions containing the formula I compound, or their salts, for use in the treatment of, for example, allergic or inflammatory diseases, or endotoxic or traumatic shock conditions; and processes for the manufacture of the formula I compounds, as well as intermediates for use in such manufacture.
- -
-
-